Merck’s Keytruda (pembrolizumab) received a rejection from the U.S. Food and Drug Administration for each of six supplemental Biologics License Applications to update the dosing frequency of the checkpoint inhibitor to include every-six-weeks administration.
Intent Solutions, an Atlanta-based company that provides technology to secure medications and track prescription adherence, is collaborating with AT&T to integrate LTE-M cellular technology into the new release of Intent’s tad dispensing system.
A panel of outside advisers to the U.S. Food and Drug Administration on Thursday voted against approving Purdue Pharma’s opioid painkiller over concerns of overdosing. The recommendation follows comments from the health regulator’s staff on Tuesday on likely errors in administering the experimental drug. The agency’s staff on Wednesday had also highlighted that a rival […]